



## Supplementary figures

### **Integrated glycoproteomics identifies a role of *N*-glycosylation and galectin-1 on myogenesis and muscle development**


Ronnie Blazev<sup>1</sup>, Christopher Ashwood<sup>2,3</sup>, Jodie L. Abrahams<sup>2</sup>, Long H. Chung<sup>4</sup>, Deanne Francis<sup>4</sup>, Pengyi Yang<sup>5,6</sup>, Kevin I. Watt<sup>1,7</sup>, Hongwei Qian<sup>1</sup>, Gregory A. Quaife-Ryan<sup>8,9</sup>, James E. Hudson<sup>8,9</sup>, Paul Gregorevic<sup>1,10,11</sup>, Morten Thaysen-Andersen<sup>2</sup>, Benjamin L. Parker<sup>1,4\*</sup>




**Supplementary Figure S1.** Released *N*-glycans from membrane-associated proteins enriched from L6 myoblasts. The glycan identifiers refer to Supplementary Table S2.



**Supplementary Figure S2.** Exoglycosidase treatment of released *N*-glycans from membrane-associated proteins enriched from L6 myoblasts. **(A)** Digestion pathways. **(B)** Digestion with broad specificity sialidase,  $\alpha$ -galactosidase or  $\beta$ -galactosidase. **(C)** Digestion with broad specificity sialidase,  $\beta$ -1,4-galactosidase or  $\beta$ -1,3/4-galactosidase.



**Supplementary Figure S3.** Quantification of (A)  $\alpha$ -2,3-NeuAc-, (B)  $\alpha$ -2,6-NeuAc-, (C) LacNAc-, (D) terminal GlcNAc, or (E)  $\alpha$ -1,3-diGal-containing *N*-glycans. (F) Transcriptomic analysis of *Ggta1* during differentiation of C2C12 cells adapted from (37). Quantification of (G) *N*-glycan capping features, (H) distribution of all glycan groups, or (I) Pauci- and oligomannose verses complex and hybrid *N*-glycans.



**Supplementary Figure S4.** Released *N*-glycans from mouse skeletal muscle. Glycan identifiers refer to Supplementary Table S5.